Recent Updates
Recently added Catalysts
NKTR

Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 39th Annual J.P....

Key Takeaway: SAN FRANCISCO , Jan. 6, 2021 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard Robin , is scheduled to present at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 11:50 a.m. Pacific

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+186%
120-day peak, hindsight
Typical move
10.2%
average across 4 past catalysts
Cash runway
~40 mo
Minimal dilution risk
Lead asset
Rezpegaldesleukin
Phase 3 · Moderate-to-Severe Atopic Dermatitis

Full Press Release Details

SAN FRANCISCO , Jan. 6, 2021 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) President and Chief Executive Officer, Howard Robin , is scheduled to present at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021 at 11:50 a.m. Pacific Time . The presentation and Q&A session will be accessible via a Webcast through a link posted on the Investor Events Calendar section of the Nektar website: https://ir.nektar.com/events-and-presentations/events . This webcast will be available for replay until February 10, 2021 .
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California , with additional operations in Huntsville, Alabama and Hyderabad, India . Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com .
Last updated: Jan 6, 2021